Literature DB >> 8740564

Why toxins!

D Fitzgerald1.   

Abstract

Toxins are potent cytotoxic proteins which gain access to the interior of mammalian cells by receptor-mediated endocytosis. However, the trafficking pathways within mammalian cells are complex and toxins must be processed to active forms while avoiding degradation by the lysosomal system. Once delivered to an appropriate intracellular location, the active toxin fragment translocates to the cell cytosol and inhibits protein synthesis. Chimeric toxins are constructed by removing the toxins natural binding domain and replacing it with an antibody or cell-binding ligand that redirects cell killing activity to cancer cells. Gaining an understanding of how toxins manoeuvre within cells is vital for improving the effectiveness of chimeric toxins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740564     DOI: 10.1006/scbi.1996.0013

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   17.012


  13 in total

1.  Regulatable killing of eukaryotic cells by the prokaryotic proteins Kid and Kis.

Authors:  Guillermo de la Cueva-Méndez; Anthony D Mills; Lorena Clay-Farrace; Ramón Díaz-Orejas; Ronald A Laskey
Journal:  EMBO J       Date:  2003-01-15       Impact factor: 11.598

Review 2.  Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.

Authors:  S B Noonberg; C C Benz
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 3.  An update on epidermal growth factor receptor inhibitors.

Authors:  Shanu Modi; Andrew D Seidman
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.075

4.  In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer.

Authors:  Kevin Hollevoet; Emily Mason-Osann; Xiu-fen Liu; Sabine Imhof-Jung; Gerhard Niederfellner; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2014-06-13       Impact factor: 6.261

5.  Soapwort Saporin L3 Expression in Yeast, Mutagenesis, and RNA Substrate Specificity.

Authors:  Hongling Yuan; Quan Du; Matthew B Sturm; Vern L Schramm
Journal:  Biochemistry       Date:  2015-07-14       Impact factor: 3.162

6.  The conjugation of an AQP1-directed immunotoxin in the study of site-directed therapy within the CNS.

Authors:  Surash Surash; Peter Nemeth; Aruna Chakrabarty; Paul Chumas
Journal:  Childs Nerv Syst       Date:  2010-11-23       Impact factor: 1.475

7.  A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.

Authors:  John E Weldon; Laiman Xiang; Jingli Zhang; Richard Beers; Dawn A Walker; Masanori Onda; Raffit Hassan; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2012-11-06       Impact factor: 6.261

8.  A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

Authors:  John E Weldon; Laiman Xiang; Oleg Chertov; Inger Margulies; Robert J Kreitman; David J FitzGerald; Ira Pastan
Journal:  Blood       Date:  2008-11-06       Impact factor: 25.476

Review 9.  A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.

Authors:  John E Weldon; Ira Pastan
Journal:  FEBS J       Date:  2011-06-02       Impact factor: 5.622

10.  Scorpion peptides: potential use for new drug development.

Authors:  Bennasr Hmed; Hammami Turky Serria; Zeghal Khaled Mounir
Journal:  J Toxicol       Date:  2013-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.